Not a Portfolio.com Insider?

Subscribe and get a FREE gift!

In This Issue of Condé Nast Portfolio

Home > Resources > Company Profiles > Merck & Company, Incorporated

Merck & Company, Incorporated (MRK)

Your Name

Your Email Address *
Send a copy to me

Recipient's Email Address *

Separate multiple email addresses (max 20) with commas.

Subject *

Message

0/1500

Email Confirmation

Richard T. Clark , CEO/President/Director/Chairman of the Board

www.merck.com

Industry: Healthcare

OPEN

LAST

PREV CLOSE

CHANGE

VOLUME

Overview

News

People

Financials

Overview

A global research-driven pharmaceutical company that discovers, develops, manufactures and markets a range of innovative products to improve human and animal health.

Portfolio Articles

Merck's Latest Headache
The drug company, reeling from nine-figure settlements for Vioxx, Vytorin, and Zetia, agrees to stump up another $650 million in a new case.
Feb 07 2008
A Big Name in Generic Drugs
Mylan expands its reach in the fast-growing market for off-patent pharmaceuticals with a $6.7 billion deal.
May 14 2007
Merck's Wild Ride
An upbeat earnings forecast and a legal victory overshadow potentially crushing regulatory news on Merck's latest drug.

Apr 13 2007
Setback for Merck on F.D.A. Ruling
A government panel rejects Merck's Arcoxia drug, the latest version of its ill-fated Vioxx.

Apr 12 2007

See more news on this company

News Feeds

Pricing, regulation squeezed drug industry in 2008 AP
Dec 31 2008
Merck spent $1.1M lobbying government in 3Q AP
Dec 30 2008
Senators probe Calif. city's groundwater pollution AP
Dec 23 2008
Schering says cholesterol drug sales falling again AP
Dec 18 2008
Sector snap: Drug company stocks rise slightly AP
Dec 16 2008
FDA accepts application for Merck HIV drug AP
Dec 12 2008
Appellate court orders new Vioxx trial in Texas AP
Dec 11 2008
Shingles vaccine hard to obtain this year AP
Dec 10 2008

Portfolio Blogs

Easing the Pain for Some Vioxx Lawyers
Nov 14 2007

Press Releases

Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager Jan-08-2009, 02:13PM EST
XplosiveStocks.com: LVS, TER, AUY, EMC, MO, MRK Hot Stocks on the Move Jan-06-2009, 08:58AM EST
UPS to Manage Most of Merck's United States Distribution Jan-06-2009, 08:00AM EST
Zacks Industry Outlook Highlights: Pfizer, Bristol-Myers, Johnson & Johnson, Merck and Eli Lilly Jan-06-2009, 06:00AM EST
Merck to Hold Fourth-Quarter 2008 Sales and Earnings Conference Call on Feb. 3 Jan-05-2009, 04:30PM EST

News From Around the Web

News

UPDATE 1-Galapagos partners with Merck, shares jump (Reuters)

Jan 09 2009
Galapagos shares rally on Merck deal (MarketWatch)

Jan 09 2009
Galapagos enters strategic alliance in diabetes and obesity with Merck & Co., Inc. (TMCnet.com)

Jan 09 2009
Galapagos, Merck form alliance to develop therapies in obesity, diabetes - Update (RTTNews)

Jan 09 2009
PPD Enters Into Partnership with Merck (WallSt.net)

Jan 09 2009
Course shows companies what NOT to put in writing (Reuters)

Jan 08 2009
New Jersey briefs (The Record, New Jersey)

Jan 07 2009
Merck seeks Gardasil OK (Boston Globe)

Jan 07 2009
UPS, Merck Enter US Distribution Pact For Drugs, Vaccines (Wall Street Journal)

Jan 07 2009
Drugmaker Merck seeks Gardasil approval for boys (USA Today)

Jan 06 2009

Employees

Number of Employees: 59,800

Revenue per Employee: $399,983

Financials

Quarterly

Annual

Income Statement	10/2008	08/2008	02/2008	10/2007
Sales	1.48 Bil.	847 Mil.	1.05 Bil.	1.03 Bil.
Gross Operating Profit	4.47 Bil.	4.98 Bil.	5.2 Bil.	5.05 Bil.
Operating Income before D & A (EBITDA)	1.56 Bil.	2.04 Bil.	2.1 Bil.	1.65 Bil.
Total Income Before Interest Expenses (EBIT)	1.4 Bil.	4.52 Bil.	-3.06 Bil.	2.19 Bil.
Total Net Income	1.09 Bil.	3.3 Bil.	-1.63 Bil.	1.53 Bil.
Basic EPS, Total	0.51	1.53	-0.75	0.7
Diluted EPS, Total	0.51	1.52	-0.75	0.7

BALANCE STATEMENT	10/2008	08/2008	02/2008	10/2007
Cash and Equivalents	NA	6.29 Bil.	5.34 Bil.	5.21 Bil.
Total Assets	NA	17.05 Bil.	15.05 Bil.	14.16 Bil.
Total Liabilities	NA	9.8 Bil.	12.26 Bil.	10.51 Bil.
Total Capitalization	NA	23.49 Bil.	22.1 Bil.	24.6 Bil.

Cash Flow	10/2008	08/2008	02/2008	10/2007
Net Cash From Continuing Operations	NA	2.53 Bil.	7 Bil.	4.65 Bil.
Net Cash From Investing Activities	NA	1.9 Bil.	-2.81 Bil.	-1.96 Bil.
Net Cash From Financing Activities	NA	-3.58 Bil.	-4.87 Bil.	-3.47 Bil.
Net Change in Cash & Cash Equivalents	NA	953.3 Mil.	-578.6 Mil.	-706.4 Mil.

Income Statement	2008	2007	2006	2005
Sales	4.15 Bil.	3.73 Bil.	3.44 Bil.	3.51 Bil.
Gross Operating Profit	20.05 Bil.	18.9 Bil.	18.57 Bil.	19.43 Bil.
Operating Income before D & A (EBITDA)	7.61 Bil.	5.96 Bil.	7.57 Bil.	8.07 Bil.
Total Income Before Interest Expenses (EBIT)	3.88 Bil.	6.72 Bil.	7.87 Bil.	8.42 Bil.
Total Net Income	3.28 Bil.	4.43 Bil.	4.63 Bil.	5.81 Bil.
Basic EPS, Total	1.51	2.04	2.11	2.62
Diluted EPS, Total	1.49	2.03	2.1	2.61

BALANCE STATEMENT	2008	2007	2006	2005
Cash and Equivalents	5.34 Bil.	5.91 Bil.	9.59 Bil.	2.88 Bil.
Total Assets	15.05 Bil.	15.23 Bil.	21.05 Bil.	13.48 Bil.
Total Liabilities	12.26 Bil.	12.72 Bil.	13.3 Bil.	11.74 Bil.
Total Capitalization	22.1 Bil.	23.11 Bil.	23.04 Bil.	21.98 Bil.

Cash Flow	2008	2007	2006	2005
Net Cash From Continuing Operations	7 Bil.	6.77 Bil.	7.61 Bil.	8.8 Bil.
Net Cash From Investing Activities	-2.81 Bil.	-4.88 Bil.	2.27 Bil.	-1.64 Bil.
Net Cash From Financing Activities	-4.87 Bil.	-5.6 Bil.	-3.04 Bil.	-5.59 Bil.
Net Change in Cash & Cash Equivalents	-578.6 Mil.	-3.67 Bil.	6.71 Bil.	1.68 Bil.